{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000832","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2022-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.583684+00:00","generated_at":"2026-06-27T10:36:13.016462+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcadia Biosciences appoints Stan Jacot as CEO; grants inducement option for 316K shares","bullets":["Stan Jacot named President and CEO effective Feb 2, 2022; previous president of Jane's Dough Foods (6-year tenure with double-digit CAGR).","Annual base salary $350,000, target bonus 50% of base; inducement stock option for 316,108 shares at $0.91 (vests over four years).","Kevin Comcowich steps down as interim CEO but remains Chairman of the Board.","Severance agreement provides 9 months base salary continuation (non-CIC) or 12 months with full equity vesting acceleration after change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000832","json":"https://secwatch.observer/filing/0000950170-22-000832.json","markdown":"https://secwatch.observer/filing/0000950170-22-000832.md","text":"https://secwatch.observer/filing/0000950170-22-000832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/0000950170-22-000832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/rkda-20220202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T10:36:13.016462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af85e2f9d5","claim":"Kevin Comcowich resigned as Interim President and Chief Executive Officer at Arcadia Biosciences, Inc..","evidence_excerpt":"In connection with Mr. Jacot’s appointment, Kevin Comcowich resigned as interim president and chief executive officer of the Company, effective February 2, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/0000950170-22-000832-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d88698e7cd","claim":"Stanley Jacot, Jr. was appointed as President and Chief Executive Officer at Arcadia Biosciences, Inc..","evidence_excerpt":"On February 2, 2022, (the “Effective Date”), Arcadia Biosciences, Inc. (“the Company”) hired Stanley Jacot, Jr. as the new president and chief executive officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/0000950170-22-000832-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}